Skip to main content

Table 1 Specificities of receptor tyrosine kinase inhibitors

From: Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2

IC50s

VEGFR1 (nM)

VEGFR2 (nM)

VEGFR3 (nM)

PDGFR (nM)

c-kit (nM)

Refs

Axitinib

0.1

0.06-0.1 (0.25)

0.1-0.3

3-30

1-2

[31]

AG-028262

~0.1

<1 (0.34)

~0.1-0.3

193

 

[39, 40]

Cediranib (AZD2171)

5

<1 (~0.5)

<1-3

5

2

[32]

Sorafenib

~26

15-90

~10-30

~10-30

68

[30, 33]

  1. Shown are IC50 values reported in the indicated references for inhibition of each human receptor protein. IC50 values for inhibition of mouse VEGFR2 are shown in parenthesis.
Back to article page

Molecular Cancer

ISSN: 1476-4598